Want to see OBIO full AI Analyst Report?
Top Page
Orchestra BioMed Holdings
(NASDAQ:OBIO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.50
▲(2.61% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily held down by weak financial performance driven by large ongoing losses and substantial cash burn, despite low leverage and a prior revenue scale-up. Technicals are supportive with strong trend and positive MACD, but overbought readings raise pullback risk. Valuation is constrained by negative earnings (negative P/E) and no stated dividend support.
Positive Factors
Revenue Scale-Up and High Gross Margin
The move from roughly $2–4M of revenue in 2022–2024 to more than $32M recently shows meaningful commercial progress. The near-99% gross margin also indicates that partnered revenue can carry substantial contribution potential.
Negative Factors
Persistent Net Losses
Large losses across the reported periods show that the current revenue base remains insufficient to support the company’s operating structure. Sustained negative profitability could require additional financing and may limit flexibility in advancing multiple programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale-Up and High Gross Margin
The move from roughly $2–4M of revenue in 2022–2024 to more than $32M recently shows meaningful commercial progress. The near-99% gross margin also indicates that partnered revenue can carry substantial contribution potential.
Read all positive factors
Orchestra BioMed Holdings (OBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$322.16M
Dividend YieldN/A
Average Volume (3M)423.89K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth986.14%
EPS Growth45.31%
CountryUS
Employees86
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.99
Shares Outstanding60,105,050
10 Day Avg. Volume206,441
30 Day Avg. Volume423,889
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.13
Price to Sales (P/S)5.92
P/FCF Ratio-4.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside86.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$548.29K
Orchestra BioMed Holdings Business Overview & Revenue Model
Company Description
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion ...
How the Company Makes Money
Orchestra BioMed’s business model is centered on monetizing its device-therapy programs through strategic collaborations rather than building a large, fully integrated commercial sales infrastructure on its own. Its revenue (when generated) can co...
Orchestra BioMed Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.98M | 33.48M | 2.64M | 2.76M | 3.53M | -782.00K |
| Gross Profit | 31.76M | 33.29M | 2.43M | 2.57M | 3.21M | -981.00K |
| EBITDA | -57.10M | -51.23M | -60.72M | -48.83M | -33.39M | -21.91M |
| Net Income | -59.03M | -52.70M | -61.02M | -49.12M | -33.61M | -23.01M |
Balance Sheet | ||||||
| Total Assets | 115.70M | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M |
| Cash, Cash Equivalents and Short-Term Investments | 109.96M | 106.51M | 66.81M | 87.59M | 83.78M | 10.90M |
| Total Debt | 70.76M | 15.96M | 16.53M | 1.69M | 11.87M | 5.67M |
| Total Liabilities | 86.28M | 51.48M | 43.22M | 27.17M | 43.04M | 84.76M |
| Stockholders Equity | 29.42M | 63.38M | 32.96M | 68.04M | 52.53M | -71.23M |
Cash Flow | ||||||
| Free Cash Flow | -59.10M | -49.45M | -50.85M | -46.20M | -29.88M | -19.70M |
| Operating Cash Flow | -58.32M | -48.96M | -50.56M | -46.13M | -29.29M | -19.43M |
| Investing Cash Flow | -69.29M | -26.94M | 13.09M | 10.69M | -64.12M | 13.02M |
| Financing Cash Flow | 129.33M | 88.33M | 29.17M | 46.22M | 103.26M | -3.99M |
Orchestra BioMed Holdings Technical Analysis
Positive
5.36
Price Trends
4.23
Positive
4.16
Positive
4.24
Positive
Market Momentum
0.38
Negative
66.84
Neutral
71.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 5.36 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 4.23, and above the 200-day MA of 4.24, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 66.84 is Neutral, neither overbought nor oversold. The STOCH value of 71.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.
Orchestra BioMed Holdings Risk Analysis
Orchestra BioMed Holdings disclosed 81 risk factors in its most recent earnings report. Orchestra BioMed Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orchestra BioMed Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.02B | -19.37 | -31.79% | ― | ― | -19.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $255.23M | -2.37 | -215.23% | ― | 291.42% | 11.70% | |
49 Neutral | $322.16M | -5.31 | -125.93% | ― | 986.14% | 45.31% | |
48 Neutral | $97.95M | -5.47 | -50.17% | ― | ― | 70.27% | |
45 Neutral | $79.35M | -1.64 | -103.08% | ― | -6.96% | 32.77% |
* Healthcare Sector Average
OBIO
Orchestra BioMed Holdings
5.26
2.55
94.10%
CRDF
Cardiff Oncology
0.98
-1.10
-52.69%
GLSI
Greenwich LifeSciences
18.23
6.77
59.08%
CLYM
Climb Bio
16.08
13.78
599.13%
CGTX
Cognition Therapeutics
1.05
-1.43
-57.66%
PYXS
Pyxis Oncology
3.34
2.01
151.13%
Orchestra BioMed Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Orchestra BioMed Shareholders Approve Directors and Incentive Plan
Positive
Jun 23, 2026
On June 23, 2026, Orchestra BioMed Holdings, Inc. held its 2026 annual meeting of stockholders, where shareholders elected three Class III directors — David P. Hochman, Darren R. Sherman and Eric S. Fain — to serve until the 2029 annua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.